Hoth Therapeutics

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On-track to initiate Phase 2 trial in Q1 2023 NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Clinical trial to begin early 2023 for Cancer patients NEW YORK , Dec. 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on December 1, 2022. The IND application supports a proposed indication of treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.

Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001

NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on November 9, 2022, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. On December 30, 2021, NASDAQ notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market.

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics (NASDAQ: HOTH ) stock is rising higher on Monday positive results from a Phase 1 clinical trial of BioLexa. BioLexa is a treatment in development at Hoth Therapeutics for mild-to-moderate atopic dermatitis in adult patients.

Why Is Hoth Therapeutics (HOTH) Stock Up 24% Today?

Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher Monday after the company announced positive BioLexa Phase 1b clinical trial results.

What's Going On With Hoth Therapeutics Stock? - Hoth Therapeutics (NASDAQ:HOTH)

MEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACY BIOLEXA led to significant improvement in disease severity as measured by SCORAD and EASI Using the EASI scale, 100% of patients showed clinically relevant improvement >50% compared to Day 1 during the entire 28-day study treatment period NEW YORK , Oct. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced positive data for BioLexa, its investigational therapeutic in a Phase 1b clinical trial in adult patients with mild-to-moderate atopic dermatitis. Using the SCORAD ("SCORing Atopic Dermatitis") as a clinical tool for assessing the severity (i.e.

HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26, 2022.

Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022

TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S. Global Acute Ischemic Stroke Market $2.7 Billion by 2029 NEW YORK , Sept. 20, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.

Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy mouse model NEW YORK , Sept. 6, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced development updates for its novel asthma and allergy maintenance therapeutic, HT-004.

Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders

NEW YORK , Aug. 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced today announced the company will be presenting at the Sidoti Investor Conference taking place on August 17-18, 2022. To learn more about the Sidoti Investor Conference or register to attend visit https://www.sidoti.com/events About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life.

Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference

Hoth Therapeutics Inc (NASDAQ: HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model. HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer'.

Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program

Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher by 17% to $0.47 Tuesday morning after the company announced its HT-ALZ therapeutic showed cognitive improvements in an Alzheimer's Disease (AD) mouse model. Hoth Therapeutics says all of the behavioral tests performed.

Why Hoth Therapeutics Shares Are Skyrocketing Today

Chronic treatment with HT-ALZ (>5 weeks) demonstrated significant improvement in behavioral and cognitive function tests in an Alzheimer's disease (AD) mouse model supporting a positive therapeutic potential of HT-ALZ for treatment of AD NEW YORK , July 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model (aged APP/PS1+/- mice), supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing. The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis.

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

NEW YORK , June 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company") today announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market ("Nasdaq") notifying the Company that Nasdaq has granted the Company an additional 180-day compliance period, or until December 26, 2022, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement (the "Additional Compliance Period"). In a letter dated December 30, 2021, Nasdaq had notified the Company that, based on the previous 30 consecutive business days, the Company's common stock no longer met the minimum $1.00 closing bid price per share requirement.

Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Blue Hat Interactive Entertainment Technology

Regis Corp.

Check out these tips for buying penny stocks in July 2022 The post What to Know About Buying Penny Stocks in July 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks in July 2022

NEW YORK , June 21, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the next phase of its BioLexa trial for patients suffering with Atopic Dermatitis. Receiving clearance is a critical milestone in our clinical trial in Australia.

Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis

NEW YORK , June 15, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 (the "Annual Meeting") was adjourned until 12:00 p.m. Eastern Time on June 23, 2022 to allow additional time to solicit proxies and obtain a quorum for the Annual Meeting.

Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022

The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials NEW YORK , June 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that it has entered into an extension of its Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ , a novel therapeutic for the treatment of Alzheimer's disease. The research will continue to be led by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine.

Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ

The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severity across three efficacy endpoints NEW YORK , May 3, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced the preliminary findings from Hoth's randomized, double-blind, placebo-controlled Phase 1b study investigating the safety and efficacy of BioLexa Lotion in patients with mild to moderate atopic dermatitis. The study is being conducted at multiple sites in Australia by the contract research organization Novotech.

Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort

Hoth Therapeutics Inc (NASDAQ: HOTH) has added a new asset, HT-TBI, as a novel, point-of-care therapy to treat secondary brain injury resulting from ischemic stroke and traumatic brain injury (TBI).  HT-TBI will be developed as a ready-to-use drug-device combination product for use.

Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury

HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and traumatic brain injury NEW YORK , April 19, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced the company is adding a new asset to its pipeline portfolio, HT-TBI, which is based on scientific research performed by Hoth. HT-TBI is being developed as a novel, point-of-care therapy for the treatment of secondary brain injury (e.g.

Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury

NEW YORK , April 14, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 8,235,294 shares of common stock (the "Common Stock") at a public offering price of $0.85 per share, priced at-the-market under Nasdaq rules, for aggregate gross proceeds of approximately $7.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,235,294 shares of Common Stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market

Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the treatment of Alzheimer's disease NEW YORK , April 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced acceptance to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 – August 4, 2022 in San Diego, California. The presentation will include results from cognitive and behavioral studies currently underway with HT-ALZ using an APP/PS1 mouse model.

Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference

NEW YORK , April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,235,294 shares of common stock (the "Common Stock") at a public offering price of $0.85 per share, priced at-the-market under Nasdaq rules, for aggregate gross proceeds of approximately $7.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,235,294 shares of Common Stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market

Hoth Therapeutics Inc (NASDAQ: HOTH) says it has commenced an underwritten public offering. Details were not disclosed.

News for Hoth Therapeutics Stock (HOTH)